Antibody-drug conjugates in solid tumors: a look into novel targets.
Antibody-drug conjugates in solid tumors: a look into novel targets.
复制标题
DOI：
10.1186/s13045-021-01035-z
复制
发表时间：
2021-01-28
影响因子：
28.5
通讯作者：
Curigliano G
中科院分区：
文献类型：
--
作者：
Criscitiello C;Morganti S;Curigliano G
抗体-药物偶联物（ADC）是一类相对较新的抗癌剂，其设计用于将单克隆抗体的选择性与化疗的细胞杀伤性质相结合。它们通常被描述为治疗设备的“特洛伊木马”，因为它们能够直接将细胞毒性药物（有效载荷）输送到肿瘤空间中，从而将化疗转化为靶向剂。最近批准了三种新型ADC，即，分别靶向HER 2、Trop 2和Nectin 4的曲妥珠单抗、德芦替康、萨希珠单抗戈维替康和恩福妥单抗维多汀。由于这些药物所依赖的工程技术的不断进步，对这些药物敏感的疾病谱及其适应症正在不断扩大。几种新型ADC正在接受评估，以探索新的潜在目标沿着创新的有效载荷。本综述旨在总结这些化合物背后的技术，并介绍最新批准用于实体瘤的ADC，以及描述正在研究的ADC的新靶点和优化其在实体瘤中疗效的新策略。
Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the “Trojan Horses” of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.
登录
查看更多内容
影响因子：
3.5
作者：
Alroy, I;Yarden, Y
通讯作者：
Yarden, Y
DOI：
10.1200/edbk_281107
发表时间：
2020-03-01
期刊：
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子：
--
作者：
Boni, Valentina;Sharma, Manish R;Patnaik, Amita
通讯作者：
Patnaik, Amita
影响因子：
45.3
作者：
Bardia, Aditya;Mayer, Ingrid A.;Vahdat, Linda T.
通讯作者：
Vahdat, Linda T.
影响因子：
11.2
作者：
Breij, Esther C. W.;de Goeij, Bart E. C. G.;Parren, Paul W. H. I.
通讯作者：
Parren, Paul W. H. I.
影响因子：
1.5
作者：
Athanassiadou, Anna Maria;Patsouris, Efstratios;Athanassiadou, Pauline
通讯作者：
Athanassiadou, Pauline